Short answer
CapsoVision, Inc (CV) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3M with net income of −$7M.
Q1 2026 key financials · XBRL
- Revenue
- $3M
- Net income
- −$7M
- Operating margin
- -254.0%
- Gross margin
- 47.6%
- EPS (diluted)
- −$0.15
Source: XBRL data from the CapsoVision, Inc (CV) Q1 2026 10-Q on SEC EDGAR. USD.
CapsoVision, Inc Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2.792M, up $9K YoY; CapsoCam Plus units sold down 3%, offset by 1% higher average selling price
- Gross margin 48% vs 54% YoY; gross profit $1.329M vs $1.494M
- Operating loss $7.093M vs $5.382M; net loss $7.033M vs $5.375M
- Cash $17.9M; operating cash outflow $6.1M vs $5.0M YoY
- CapsoCam Colon 510(k) submission targeted for third quarter 2026; substantial doubt about going concern and need for additional financing
Risk Factors
- Going-concern risk intensified: cash approximately $17.9 million at March 31, 2026, with additional financing likely before year-end 2026
- Regulatory risk: FDA Breakthrough Device Designation for pancreatic-cancer detection was not approved in January 2026
- Operational risk: Taiwan assembly manufacturers and single-source suppliers face disruption from Taiwan Strait tensions
- Competitive risk: Medtronic has greater brand recognition and financial resources in small-bowel capsule endoscopy
- Market risk: international sales increased to approximately 28% of revenue from 23% in the prior-year quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CapsoVision, Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.